The pharmaceutical industry is facing a ‘tidal wave’ of complex age and behaviour related diseases creating increased economic, scientific and delivery risks. How can pharma companies evolve to overcome these obstacles?
New research from the Deloitte UK Centre for Health Solutions looks at the changing pattern of diseases and its implications for the industry whilst highlighting a series of bold choices. The report proposes that pharma companies should focus on de-risking and delivering greater value to healthcare systems to deal with the threats facing the industry and to succeed in the 21st century.
In response to the scientific, economic, and delivery risks, our report suggests seven strategies for developing the pharma business model.